Targeting Lp(a) to reduce ASCVD risk
- PMID: 32699405
- DOI: 10.1038/s41569-020-0425-5
Targeting Lp(a) to reduce ASCVD risk
Comment on
-
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.JAMA Cardiol. 2020 Oct 1;5(10):1136-1143. doi: 10.1001/jamacardio.2020.2413. JAMA Cardiol. 2020. PMID: 32639518 Free PMC article. Clinical Trial.
References
Original article
-
- Puri, R. et al. Effect of C-reactive protein on lipoprotein(a)-associated cardiovascular risk in optimally treated patients with high-risk vascular disease: a prespecified secondary analysis of the ACCELERATE trial. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2020.2413 (2020) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
